Department of Pharmacology, Basaveshwara Medical College and Hospital, Chitradurga, Karnataka, India.
Research Article
International Journal of Science and Research Archive, 2024, 11(01), 841–848.
Article DOI: 10.30574/ijsra.2024.11.1.0021
Received on 29 November 2023; revised on 14 January 2024; accepted on 17 January 2024
Aim: To analyse the effects of combination therapy with Injection liposomal Amphotericin B (LAmB) and Tablet Posaconazole in Mucormycosis.
Acute invasive fungal sinusitis is an uncommon disease that often has rapid and destructive clinical progression. Priorly, a disease of the immuno-compromised, Invasive fungal sinusitis is typically associated with patients undergoing chemotherapy, stem cell transplantation as well as in patients with uncontrolled diabetes mellitus and patients using corticosteroids.
Materials and methods: This retrospective observational study was carried after obtaining institutional ethical committee on a total of 40 patients with history of diabetes mellitus, covid positivity, infusion of steroid injections and immuno-compromised were admitted and treated between May 2021 to July 2021.
Results: Any potential combination therapy study under consideration for testing in patients with Mucormycosis should use polyene, as backbone therapy. Injection Amphotericin B remains the only antifungal agent licensed by the US Food and Drug Administration for primary therapy of Mucormycosis.
Tablet Posaconazole reported 90% minimum inhibitory concentrations with Mucorales range from 1 to >=4 microgram/ml. In febrile neutropenic patients or those with mucormycosis,
Conclusion: Mucormycosis is a disease of increasing frequency. It continues to have a higher mortality rate than most other infections, frequently affects young patients.
Mucormycosis; Treatment; Diabetes mellitus; Mucorales
